1. Home
  2. KPET vs ARCT Comparison

KPET vs ARCT Comparison

Compare KPET & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KPET Ultra Paceline Corporation Class A Ordinary Shares

KPET

KPET Ultra Paceline Corporation Class A Ordinary Shares

N/A

Current Price

$10.00

Market Cap

289.9M

Sector

N/A

ML Signal

N/A

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

N/A

Current Price

$9.29

Market Cap

293.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KPET
ARCT
Founded
2025
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
289.9M
293.9M
IPO Year
2026
2019

Fundamental Metrics

Financial Performance
Metric
KPET
ARCT
Price
$10.00
$9.29
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
★ $23.80
AVG Volume (30 Days)
41.3K
★ 659.1K
Earning Date
N/A
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 20.00
EPS
★ N/A
N/A
Revenue
N/A
★ $82,031,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$27.62
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.95
$5.50
52 Week High
$10.05
$17.96

Technical Indicators

Market Signals
Indicator
KPET
ARCT
Relative Strength Index (RSI) 50.36 40.82
Support Level $9.99 $9.13
Resistance Level $10.02 $12.44
Average True Range (ATR) 0.00 1.08
MACD 0.00 -0.06
Stochastic Oscillator 36.36 4.68

Price Performance

Historical Comparison
KPET
ARCT

About KPET KPET Ultra Paceline Corporation Class A Ordinary Shares

KPET Ultra Paceline Corp is a Blank Check company. It is formed with the objective of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Share on Social Networks: